<DOC>
	<DOCNO>NCT00239421</DOCNO>
	<brief_summary>To compare efficacy safety tiotropium plus formoterol comparison salmeterol plus fluticasone COPD patient .</brief_summary>
	<brief_title>A Six-week Study Comparing Efficacy Safety Tiotropium Plus Formoterol Salmeterol Plus Fluticasone Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>Tiotropium ( Spiriva® ) once-daily inhaled anticholinergic treatment COPD . A six-week , multicentre , randomize , double-blind , parallel group study conduct compare efficacy safety free combination tiotropium 18 µg daily plus formoterol 12 µg b.i.d . [ Tio+For ] salmeterol 50 µg b.i.d . plus fluticasone 500 µg b.i.d . [ Sal+Flu ] COPD patient . Information regard differential efficacy safety two different combination may essential physician make informed choice therapy COPD patient consider candidate combination therapy . Following initial screen visit , subject enter two four-week run-in period receive ipratropium ( Atrovent® ) regular basis . At second visit ( Baseline ) , subject randomize six-week , double blind portion study receive either Tio+For Sal+Flu . After three week treatment , interim visit schedule . After six week treatment , 12-hour profile pulmonary function testing ( FEV1 , FVC ) obtain . Spirometric measurement perform pre-dose 30 minute , 1 , 2 , 3 , 4 , 6 , 8 , 10 12 hour post-dosing . There two co-primary endpoint : FEV1 area curve time period 0 12 hour ( FEV1 AUC0-12 ) peak FEV1 . The efficacy evaluation ( intention-to-treat ) comprise 592 patient [ Tio+For : N=297 , Sal+Flu : N=295 ] . The two treatment group comparable regard demographic data baseline disease characteristic [ Baseline FEV1 ( ±SE ) : Tio+For : 1.310 L ( ±0.026 L ) ; Sal+Flu : 1.325 L ( ±0.025 L ) ] . Adjustment do baseline centre-effects . Study Hypothesis : The following primary hypothesis ( one-sided ) test regard superiority ( mean adjust mean ) : H01 : FEV1AUC ( 0-12 hour ) ( tiotropium+formoterol ) &lt; = FEV1AUC ( 0-12 hour ) ( salmeterol+fluticasone ) versus H11 : FEV1AUC ( 0-12 hour ) ( tiotropium+formoterol ) &gt; FEV1AUC 0-12 hour ( salmeterol+fluticasone ) It stipulate protocol , null hypothesis H01 reject favour H11 , follow hypothesis would test : H01 : Peak FEV1 ( tiotropium+formoterol ) &lt; = Peak FEV1 ( salmeterol+fluticasone ) versus H11 : Peak FEV1 ( tiotropium+formoterol ) &gt; Peak FEV1 ( salmeterol+fluticasone ) Each step consider confirmatory provide previous step successful . If previous step successful , analysis current step would consider descriptive . Comparison ( ) : Test therapy : Test product : Tiotropium inhalation capsule plus formoterol inhalation capsule Dose : 18 µg tiotropium per day ( one capsule ) , 12 µg formoterol twice daily ( two time one capsule ) Mode administration : inhalation via Handihaler device ( tiotropium ) , inhalation via Blue Inhaler device ( formoterol ) Reference therapy : Test product : Salmeterol plus fluticasone propionate Dose : Salmeterol 50 µg ( 2 puff 25 µg ) b.i.d. , fluticasone propionate 500 µg ( 2 puff 250 µg ) b.i.d . Mode administration : inhalation via MDI The treatment duration 42 day . Primary endpoint measurement perform last treatment day .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>1 . All patient must sign informed consent prior participation trial , include medication washout restriction . 2 . All patient must diagnosis chronic obstructive pulmonary disease accord GOLD criterion must meet follow spirometric criterion : postbronchodilator FEV1 &lt; 80 % predict normal , postbronchodilator FEV1/FVC &lt; 70 % Visit 1 , morning FEV1 &lt; = 65 % predict Visit 2 . 3 . Male female patient 40 year age old . 4 . Patients must current exsmokers smoke history 10 packyears . 5 . Patients must able perform technically acceptable pulmonary function test . 6 . Patients must able inhale medication competent manner HandiHaler® device , Blue Inhaler device , meter dose inhaler ( MDI ) . 1 . Patients significant disease COPD . 2 . Patients recent history ( i.e. , six month less ) myocardial infarction . 3 . Patients hospitalized heart failure ( NYHA class III IV ) within past year . 4 . Any unstable life threaten cardiac arrhythmia cardiac arrhythmia require intervention change drug therapy within past year . 5 . Patients history cancer within last five year . 6 . Patients know narrowangle glaucoma . 7 . Patients history asthma , allergic rhinitis atopy total blood eosinophil count &gt; = 600/mm3 . 8 . Patients history life threaten pulmonary obstruction , history cystic fibrosis clinically evident bronchiectasis . 9 . Patients know active tuberculosis . 10 . Patients significant alcohol drug abuse within past two year . 11 . Patients undergone thoracotomy pulmonary resection . 12 . Patients complete pulmonary rehabilitation program six week prior Screening Visit ( Visit 1 ) patient currently pulmonary rehabilitation program maintain throughout study . 13 . Patients regularly use daytime oxygen therapy one hour per day investigator 's opinion unable abstain use oxygen therapy . 14 . Patients treated antihistamine ( H1 receptor antagonist ) asthma exclude allergic condition . 15 . Patients take investigational drug within one month six half life prior Visit 1 . 16 . Patients treat oral betaadrenergics within one month prior Visit 1 . 17 . Patients treat antileukotrienes leukotriene receptor antagonist disease within one month prior Visit 1 . 18 . Patients treat oral steroid within six week prior Visit 1 . 19 . Patients treat monoamine oxidase inhibitor tricyclic antidepressant within one month prior Visit 1 . 20 . Patients treat cromolyn sodium nedocromil sodium within one month prior Visit 1 . 21 . Patients treat inhaled steroid within two month prior Visit 1 , include combination inhale steroid longacting betaadrenergics . 22 . Patients know hypersensitivity anticholinergic drug , beta adrenergic , lactose component inhalation capsule delivery system component aerosol delivery system . 23 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception previous three month . 24 . Patients respiratory infection six week prior Screening Visit ( Visit 1 ) runin period . 25 . Patients currently participate another study . 26 . Patients require eight puff salbutamol three consecutive day runin period .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>